InnoCare Pharma’s experimental oral BTK inhibitor, called orelabrutinib, succeeded in a mid-stage trial in systemic lupus erythematosus (SLE), the Chinese biotech said Sunday.
After nearly a year’s worth treatment with the ...
↧